About HeartBeat.bio

HeartBeat.bio is developing a high-throughput 3D screening platform that utilizes human organoid technologies and artificial intelligence to enhance cardiac drug discovery. This approach addresses the inefficiencies in traditional drug development methods by providing more accurate and relevant biological models for testing potential therapies.

```xml <problem> Traditional cardiac drug discovery methods often rely on animal models or 2D cell cultures that fail to accurately replicate human heart physiology, leading to high failure rates in clinical trials. Existing in vitro models lack the structural complexity and cell-cell interactions necessary to mimic human heart development and disease. This results in inefficient screening processes and inaccurate prediction of drug efficacy and toxicity. </problem> <solution> HeartBeat.bio offers a high-throughput 3D screening platform that utilizes human cardiac organoids, termed Cardioids, to improve the accuracy and efficiency of cardiac drug discovery. The platform guides induced pluripotent stem cells (iPSCs) to self-organize into beating, hollow, spherical chambers that mimic human heart development and physiology. These Cardioids replicate the native architecture of key cardiac cell types, maintaining a consistent, physiologically relevant beating pattern, providing a more predictive model for cardiac diseases. By integrating these cardiac models with specialized assays in an automated, industry-standard 384-well format, HeartBeat.bio delivers a scalable and cost-effective platform for advanced, disease-relevant drug testing and discovery. The platform also incorporates AI-powered analytics to provide deep, clinically relevant insights that accelerate and de-risk cardiac drug discovery. </solution> <features> - Generation of self-organizing Cardioids from iPSCs, replicating human heart chamber structure and function - Customizable models for heart diseases, including myocardial fibrosis and genetic cardiomyopathies - Comprehensive assay suite for characterizing heart disease phenotypes at structural, functional, and molecular levels - Fully automated, industry-standard 384-well format for high-throughput screening - AI-driven data analytics for predictive insights and target discovery - Proprietary technology enabling precise control over cellular composition within the Cardioids - Integrated quality control measures to ensure reproducibility and reliability of results </features> <target_audience> The primary customers are pharmaceutical companies, biotech firms, and research institutions involved in cardiac drug discovery and development. </target_audience> ```

What does HeartBeat.bio do?

Where is HeartBeat.bio located?

HeartBeat.bio is based in Vienna, Austria.

When was HeartBeat.bio founded?

HeartBeat.bio was founded in 2021.

How much funding has HeartBeat.bio raised?

HeartBeat.bio has raised 11100000.

Location

Vienna, Austria

Founded

2021

Funding

11100000

Employees

23 employees

Major Investors

INVEST AG, aws Gründungsfonds

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

HeartBeat.bio

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

heartbeat.bio 2K+

Crunchbase

Founded 2021 – Vienna, Austria

Funding

Estimated Funding

$10M+

Major Investors

INVEST AG, aws Gründungsfonds

Team (20+)

No team information available.

Company Description

Problem

Traditional cardiac drug discovery methods often rely on animal models or 2D cell cultures that fail to accurately replicate human heart physiology, leading to high failure rates in clinical trials. Existing in vitro models lack the structural complexity and cell-cell interactions necessary to mimic human heart development and disease. This results in inefficient screening processes and inaccurate prediction of drug efficacy and toxicity.

Solution

HeartBeat.bio offers a high-throughput 3D screening platform that utilizes human cardiac organoids, termed Cardioids, to improve the accuracy and efficiency of cardiac drug discovery. The platform guides induced pluripotent stem cells (iPSCs) to self-organize into beating, hollow, spherical chambers that mimic human heart development and physiology. These Cardioids replicate the native architecture of key cardiac cell types, maintaining a consistent, physiologically relevant beating pattern, providing a more predictive model for cardiac diseases. By integrating these cardiac models with specialized assays in an automated, industry-standard 384-well format, HeartBeat.bio delivers a scalable and cost-effective platform for advanced, disease-relevant drug testing and discovery. The platform also incorporates AI-powered analytics to provide deep, clinically relevant insights that accelerate and de-risk cardiac drug discovery.

Features

Generation of self-organizing Cardioids from iPSCs, replicating human heart chamber structure and function

Customizable models for heart diseases, including myocardial fibrosis and genetic cardiomyopathies

Comprehensive assay suite for characterizing heart disease phenotypes at structural, functional, and molecular levels

Fully automated, industry-standard 384-well format for high-throughput screening

AI-driven data analytics for predictive insights and target discovery

Proprietary technology enabling precise control over cellular composition within the Cardioids

Integrated quality control measures to ensure reproducibility and reliability of results

Target Audience

The primary customers are pharmaceutical companies, biotech firms, and research institutions involved in cardiac drug discovery and development.